Please assess the completion status of the following clinical trial:

Trial Title: Autologous Skin Substitute for Chronic Leg/Foot Ulcers.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Have a (arterio) venous leg ulcer (VLU) between the knee and ankle (at or above the malleolus), or on foot (not plantar side of the foot) with a surface area ≥ 1.0 cm2 and ≤ 40.0 cm2~* Venous insufficiency confirmed by duplex Doppler ultrasound examination for valvular or venous incompetence.~* Arterial supply adequacy confirmed (ABPI ≥ 0.6 and ≤ 1.3)~* Target ulcer involves a full thickness skin loss, but WITHOUT exposure of tendon, muscle, or bone. Ulcer depth \< 1 cm~* Target ulcer duration ≥ 12 weeks but ≤ 15 years~* Acceptable state of health and nutrition~* Mobile, at least able to walk with medical walker, and able to return for required treatments and study evaluations~Exclusion Criteria:~* History of anaphylaxis, serum sickness, or erythema multiforme reaction to bovine serum proteins, gentamycin.~* Therapy with another investigational agent within thirty (30) days of Screening, or during the study.~* A target ulcer of non-venous etiologies (e.g., sickle cell anemia, necrobiosis lipoidica diabeticorum, pyoderma gangrenosum, vasculopathic or vasculitic).~* Documented history of osteomyelitis at the target wound location within 6 months preceding the Screening Visit.~* Refusal of or inability to tolerate compression therapy.~* Therapy of the target ulcer with autologous skin graft, Apligraf™, or Dermagraft™ within 30 days preceding the Screening Visit.~* History of cancer in the preceding 5 years (other than carcinoma in situ of the cervix or adequately treated non-melanoma skin cancers).~* \>30% change of wound size in 4 weeks or confirmed by historical data~* Presence of deep vein thrombosis or contra indication for compression therapy~* Severe co-morbidity reducing life expectance to \< 1 year~* Use of oral corticosteroids and/or cytostatics \>20 mg/per day;~* Severe infection of ulcer, active cellulitis, osteomyelitis~* Severe malnutrition~* Uncontrolled diabetes mellitus, HbA1c \> 12% (108 mmol/mol)~* Anaemia Hb \<6 mmol/l

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- autologous cultured skin (Type: EXPERIMENTAL): autologous cultured skin patches (Tiscover) is applied on wound in 2-step procedure with 1 week interval. Dosage: number of patches depends on wound size. Application week 0 is removed after one week (week1). Week 1: wound is completely covered with new Tiscover patches.
- acellular donor dermis (Type: ACTIVE_COMPARATOR): acellular donor dermis (AS210) is applied on wound in 2-step procedure with 1 week interval. Dosage: number of patches depends on wound size.~Application week 0 is removed after one week (week1). Week 1: wound is completely covered with new AS210 patches.

Based on this trial design, predict the completion outcome and termination type (if applicable).